Mazar Andrew Paul
CIK 0001727393
Chief Scientific OfficerDirector
Filings
8
Latest Apr 1, 2026
Issuers covered
2
Showing
8 of 8
Page 1
Track record
2 of 2 open-market trades scored (100% price coverage). Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 2 | 0% | -14.2% | -14.2% | -11.7% | -16.7% |
| 90 days | 2 | 100% | +8.2% | +8.2% | +12.9% | +3.5% |
| 180 days | 2 | 50% | -37.0% | -37.0% | +23.0% | -97.0% |
| 365 days | 1 | 0% | -43.1% | -43.1% | -43.1% | -43.1% |
Issuers
Companies where Mazar Andrew Paul has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| MNPR | Monopar Therapeutics | 6 | Sep 26, 2025 |
| ACTU | Actuate Therapeutics, Inc. | 2 | Apr 1, 2026 |
All filings
8 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|